Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2008-02-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.2007.083162PMID 18250115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.

  2008cited by this paper
• Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.

  2007cited by this paper
• Prospective Phase 1/2 Study of Rituximab in Childhood and Adolescent Chronic Immune Thrombocytopenic Purpura

  2007cited by this paper
• Serum sickness following treatment with rituximab.

  2007cited by this paper
• A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

  2007cited by this paper
• Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

  2007cited by this paper
• Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature.

  2007cited by this paper
• Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

  2007cited by this paper
• Rituximab-induced long-term remission of membranous lupus nephritis.

  2006cited by this paper
• Review of Progressive Multifocal Leukoencephalopathy and Natalizumab

  2006cited by this paper
• A Case for Regulatory B Cells1

  2006cited by this paper
• B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus

  2006cited by this paper
• B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.

  2006cited by this paper
• Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus.

  2006cited by this paper
• Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.

  2006cited by this paper
• Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

  2005cited by this paper
• Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174

  2005cited by this paper
• Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

  2005cited by this paper
• B Lymphocytes Are Required for Development and Treatment of Autoimmune Diseases

  2005cited by this paper
• B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

  2005cited by this paper
• Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

  2005cited by this paper
• Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.

  2004cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004cited by this paper
• B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells

  2004cited by this paper
• B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

  2004cited by this paper
• Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?

  2004cited by this paper
• Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

  2004cited by this paper
• The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

  2004cited by this paper
• B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment.

  2004cited by this paper
• B cells in human and murine systemic lupus erythematosus

  2004cited by this paper
• Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

  2004cited by this paper
• Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

  2003cited by this paper
• B cell depletion therapy in systemic lupus erythematosus

  2003cited by this paper
• Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

  2003cited by this paper
• Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy.

  2002cited by this paper
• Rituximab treatment results in impaired secondary humoral immune responsiveness.

  2002cited by this paper
• An open study of B lymphocyte depletion in systemic lupus erythematosus.

  2002cited by this paper
• Specific antibody response after influenza immunization in systemic lupus erythematosus.

  2002cited by this paper
• Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus.

  2002cited by this paper
• Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

  2001cited by this paper
• T Cell Activation in Rheumatoid Synovium Is B Cell Dependent1

  2001cited by this paper
• Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

  2001cited by this paper
• Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma

  2001cited by this paper
• Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus1

  2000cited by this paper
• Accurately describing changes in disease activity in Systemic Lupus Erythematosus.

  2000cited by this paper
• The central and multiple roles of B cells in lupus pathogenesis

  1999cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper
• Antigen-specific antibody responses in lupus patients following immunization.

  1998cited by this paper
• Derivation of the SLEDAI.

  1993cited by this paper
• Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

  1992cited by this paper
• Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.

  1989cited by this paper
• Measurement of systemic lupus erythematosus activity in clinical research.

  1988cited by this paper
• Giles of Rome.

  1981cited by this paper
• Late mortality in SLE--"the price we pay for control".

  1980cited by this paper
• Late mortality in SLE--"the price we pay for control".

  1980cited by this paper
• Disease activity in systemic lupus erythematosus

  1979cited by this paper
• A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus.

  1979cited by this paper

• Anti-CD20 therapy in lupus nephritis: A revisit

  2025cites this paper
• Opportunities and limitations of B cell depletion approaches in SLE

  2025cites this paper
• [Anti-rituximab antibodies in autoimmune diseases and hematologic malignancies: An update].

  2025cites this paper
• Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.

  2025cites this paper
• The effect of Rituximab on B cells in pediatric autoimmune rheumatic diseases

  2025cites this paper
• Unraveling the Landscape of Rituximab Resistance in Diffuse Large B-Cell Lymphoma

  2025cites this paper
• Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management

  2025cites this paper
• Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus

  2024cites this paper
• Rituximab Resistance in Glomerular Diseases: A GlomCon Mini Review

  2024cites this paper
• Dawn of CAR-T cell therapy in autoimmune diseases

  2024cites this paper
• B Cell-Directed Therapy in Autoimmunity.

  2023cites this paper
• Current treatment of systemic lupus erythematosus: a clinician's perspective

  2023cites this paper
• Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment

  2023cites this paper
• Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.

  2023cites this paper
• Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases

  2023cites this paper
• Circulating lymphocyte subpopulations in patients with systemic lupus erythematosus and their correlation with disease activity

  2023cites this paper
• B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study

  2023cites this paper
• Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial

  2022cites this paper
• Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus

  2022cites this paper
• Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.

  2022cites this paper
• Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome

  2022cites this paper
• Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus.

  2022cites this paper
• Lupus, vaccinations and COVID-19: What we know now

  2021cites this paper
• Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

  2021cites this paper
• RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS

  2021cites this paper
• The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies.

  2021cites this paper
• Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients

  2021cites this paper
• Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

  2021cites this paper
• On the road to eliminating long‐lived plasma cells—“are we there yet?”

  2021cites this paper
• Emerging B-Cell Therapies in Systemic Lupus Erythematosus

  2021cites this paper
• Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?

  2021cites this paper
• Targeting B Lymphocytes Using Protein‐Functionalized Graphene Oxide

  2021cites this paper
• Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome

  2021cites this paper
• Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab

  2020cites this paper
• Circulating MicroRNAs as potential biomarkers for monitoring the response to in vivo treatment with rituximab in systemic lupus erythematosus patients.

  2020cites this paper
• Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

  2020cites this paper
• Patients with systemic lupus erythematosus show increased proportions of CD19+CD20− B cells and secretion of related autoantibodies

  2020cites this paper
• Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome

  2020cites this paper
• B cells targeting therapy in the management of systemic lupus erythematosus

  2020cites this paper
• Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus.

  2020cites this paper
• Rituximab bioavailability in primary membranous nephropathy.

  2019cites this paper
• PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES

  2019cites this paper
• 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

  2019influential citation
• Moving Forward With Biologics in Lupus Nephritis.

  2019cites this paper
• RTX bioavalability in MN Boyer-Suavet NDT 2019

  2019cites this paper
• Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study.

  2019cites this paper
• Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review

  2019cites this paper
• Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus

  2019cites this paper
• Immunosuppressive therapy with rituximab in common variable immunodeficiency

  2019cites this paper
• Desloratadine induced headache: Are we noticing or missing it?

  2019cites this paper
• B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments

  2019cites this paper
• B Cell Biology and Related Therapies in SLE

  2019cites this paper
• Delayed-onset serum sickness due to rituximab in pemphigus vulgaris

  2019cites this paper
• Selective HDAC6 inhibition decreases early stage of lupus nephritis by down‐regulating both innate and adaptive immune responses

  2018cites this paper
• Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus

  2018cites this paper
• Targeting B Cells and Plasma Cells in Autoimmune Diseases

  2018cites this paper
• EVIEW ituximab in dermatology

  2018cites this paper
• Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab

  2018cites this paper
• Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study

  2018cites this paper
• Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

  2018cites this paper
• Outcomes of rituximab therapy in refractory lupus: A meta-analysis.

  2018cites this paper
• Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.

  2018cites this paper
• Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice

  2018cites this paper
• Rituximab treatment of myasthenia gravis: A systematic review

  2017cites this paper
• Rituximab for immunologic renal disease: What the nephrologist needs to know.

  2017cites this paper
• ituximab in dermatology

  2017cites this paper
• Lupus nephritis and B-cell targeting therapy

  2017cites this paper
• Anti-CD20 monoclonal antibodies immuno-monitoring in primary membranous nephropathy to guide personalized treatment

  2017cites this paper
• Selective HDAC 6 inhibition decreases early stage of lupus nephritis by downregulating both innate and adaptive immune responses Short : HDAC 6 inhibition decreases early stage of lupus nephritis

  2017cites this paper
• Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art

  2017cites this paper
• Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long‐Term Effects on Serum Immunoglobulins

  2017cites this paper
• Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis

  2017cites this paper
• 12 New Therapeutic Strategies in Lupus Nephritis

  2017cites this paper
• Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity.

  2017cites this paper
• Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review

  2017cites this paper
• Use of polyclonal/monoclonal antibody therapies in transplantation

  2017cites this paper
• Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy

  2017cites this paper
• Current perspective on rituximab in rheumatic diseases

  2017cites this paper
• B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients

  2017cites this paper
• Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab.

  2017cites this paper
• Risk of clinical deterioration in patients with lupus nephritis receiving rituximab

  2016cites this paper
• Inflammation Causes Resistance to Anti‐CD20–Mediated B Cell Depletion

  2016cites this paper
• Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus

  2016cites this paper
• Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis

  2016cites this paper
• Atypical Multiple Cutaneous Ulcers in A Patient with Systemic Lupus Erythematosus Treated with Rituximab: Case Report

  2016cites this paper
• Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.

  2016cites this paper
• Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab

  2016cites this paper
• Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients

  2016cites this paper
• A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE.

  2015cites this paper
• Longer duration of B cell depletion is associated with better outcome.

  2015cites this paper
• Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

  2015cites this paper
• Current role of rituximab in systemic lupus erythematosus

  2015cites this paper
• Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine

  2015cites this paper
• B Cells, Antibodies, and More.

  2015cites this paper
• B cells participate in tolerance and autoimmunity through cytokine production

  2014cites this paper
• Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?

  2014cites this paper
• Update on Rituximab: An Established Treatment for All Immune-Mediated Kidney Diseases?

  2014cites this paper
• Development of antirituximab antibodies in children with nephrotic syndrome

  2014cites this paper
• Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

  2014influential citation
• Pharmacological Effects and Mechanisms of Action of Agents Blocking B Cells

  2014cites this paper